Venous thrombosis of sarcoidosis as an unusual incidental finding on 18F-fluorodeoxyglucose positron emission tomography/computed tomography

Seval Erhamamci, Mehmet Reyhan, Ali Fuat Yapar, Tuba Canpolat

Departments of Nuclear Medicine and 1Pathology, Faculty of Medicine, Baskent University, Turkey

ABSTRACT
Sarcoidosis is defined as a multisystem granulomatous disorder of unknown cause. Venous thrombosis (VT) in the sarcoidosis is rare. The routine use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has resulted in clinicians detecting many incidental findings, which have proven to be clinically significant such as thrombosis. Here, we present a case with VT of sarcoidosis in the inferior vena cava and portal vein as an unusual incidental finding on 18F-FDG PET/CT.

Keywords: 18F-fluorodeoxyglucose, positron emission tomography/computed tomography, sarcoidosis, venous thrombosis

A 56-year-old man was admitted to the hospital due to cough, chest and back pain during 4-month. A computed tomography (CT) of the chest revealed mediastinal lymphadenopathy and lung parenchymal lesion. The patient underwent 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) imaging due to suspected lung cancer. The image showed abnormal 18F-FDG uptake in the mediastinal, abdominal, and pelvic lymph nodes, and lungs [Figure 1a]. The images also demonstrated hypermetabolic activity in the inferior vena cava and portal vein (PV) consistent with lesions of thrombosis [Figure 1a-e]. These images were highly suggestive of lung cancer, widespread lymph nodes metastases, and tumor thrombosis in the IVC and PV. Biopsy of the mediastinal lymph node by mediastinoscopy revealed a noncaseating epithelial granulomatous lesion [Figure 2]. The patient was diagnosed as sarcoidosis and venous thrombosis (VT) in the IVC and PV. As the final diagnosis of a benign disease was determined, regular follow-up by plain radiography was planned, the patient recovered spontaneously without treatment [Figure 3].

Address for correspondence:
Dr. Seval Erhamamci, Department of Nuclear Medicine, Faculty of Medicine, Baskent University, Saray Street No. 1, 42080, Selcuklu, Konya, Turkey. E-mail: sevaler@yahoo.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Erhamamci S, Reyhan M, Yapar AF, Canpolat T. Venous thrombosis of sarcoidosis as an unusual incidental finding on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Indian J Nucl Med 2015;30:352-4.
Sarcoidosis is defined as a multisystem granulomatous disorder of unknown cause. Lungs and thoracic lymph nodes are most commonly involved. Extrathoracic manifestations, usually associated with thoracic involvement, are seen in 25–50% of cases. VT in the sarcoidosis is rare. In the literature, there are few reported cases of sarcoidosis with VT, such as pulmonary embolism, thrombosis of brachiocephalic vein, upper and lower extremities veins, dural sinus, renal vein, retinal veins, PV, and intracardiac thrombi. Also, both arterial and VT, multiple venous thrombi, widespread and recurrent thrombophlebitis and the antiphospholipid syndrome has also been described in sarcoidosis.

VT results from a combination of hereditary and acquired factors. All these etiological factors are found among Virchow’s triad of hypercoagulability, endothelial injury, and venous stasis. Hypercoagulability related to hematological or neoplastic processes, venous stasis secondary to compression from a tumor, hematoma, or infectious process, and endothelial injury due to trauma or foreign body have all been implicated in the pathophysiology of VT. The list of known acquired risk factors has also grown in recent years. Other acquired predispositions to VT include acquired thrombophilias (antiphospholipid antibody syndrome), as well as environmental factors (combined oral contraceptive pill, hormone replacement therapy, pregnancy, obesity, malignancy, and chronic inflammatory conditions). Recent reports have further shown that a majority of autoimmune and immune-mediated disorders are linked to an increased risk of VT. Vena cava and PV thrombosis is frequently associated with neoplastic disease. We present a case of sarcoidosis as an uncommon benign cause of IVC and PV thrombosis. Although the exact mechanism of thrombus formation in sarcoidosis is not yet known, venous stasis secondary to lymph node compression, local tissue thrombophilia in involved organs, and granulomatous phlebitis are potential mechanisms. Although prothrombotic conditions workup was not performed, there was no any predisposing history for thrombosis in the present case. The development of the PV and IVC thrombosis in the present case may be owing to extrinsic compression.

18F-FDG PET/CT has been widely used in the diagnosis and follow-up of suspected or known malignancy. However, infection or inflammation such as osteomyelitis, tuberculosis, and sarcoidosis can also exhibit increased 18F-FDG uptake. Thus, 18F-FDG PET/CT have also been increasingly used for the assessment of infectious and inflammatory diseases, including sarcoidosis. The routine use of 18F-FDG PET/CT has resulted in clinicians detecting many incidental findings, which have proven to be clinically significant such as thrombosis. The recognition of this rare complication by 18F-FDG PET/CT is essential for the accurate management of patients. We report, to our knowledge, the first case of sarcoidosis with VT as an incidental finding on 18F-FDG PET/CT. VT is a well-recognized, relatively common complication in cancer patients and a significant cause of morbidity and mortality. VT is managed with anticoagulant therapy. In contrast to tumor thrombosis is another known cause of thrombosis in patients with cancer requires aggressive multimodality management. Therefore, the correct diagnosis of VT can change patient management and might facilitate the start of anticoagulant therapy. However, so far, there is no definitive strategy to manage thrombosis in sarcoidosis. There are no officially approved guidelines or consensus management available regarding the treatment of sarcoidosis as it is a rare disease with rarer clinical manifestations. Therefore, most of the management decisions have to be individualized depending on the local expertise. In our case, there was no specific treatment initiated for IVC and PV thrombosis as he is currently asymptomatic. It was planned to keep him in regular follow-up. Further research is needed to elucidate the exact cause of thrombosis and defining management modalities of thrombosis in sarcoidosis. We think that any reported similar case will be of great interest as a guide to better assess the outcomes of patients with sarcoidosis.

**Financial support and sponsorship**
Nil.
Conflicts of interest
There are no conflicts of interest.

REFERENCES